Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.59
$0.046.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.75% | 5.89% | -2.77% | 25.18% | -6.44% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.55% | -55.22% | 51.76% | 105.04% | 73.72% |
| Change in Net Operating Assets | -414.44% | 125.07% | 23.11% | -188.51% | 596.59% |
| Cash from Operations | -11.51% | 38.83% | 9.96% | -114.56% | 49.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.89% | 52.50% | -25.21% | -50.04% | 0.00% |
| Issuance of Common Stock | -16.43% | 4,129.82% | -98.55% | 344.21% | 33.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -16.64% | 138,079.45% | -99.96% | 369.84% | 35.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.44% | 161.98% | -203.40% | 1,378.25% | 89.31% |